Tags

Type your tag names separated by a space and hit enter

Rationale for the development of a novel gastrointestinal prokinetic, cisapride.
Scand J Gastroenterol Suppl 1989; 165:1-6; discussion 27-8SJ

Abstract

Several promotility drugs have been used to correct disorders caused by disturbed gastrointestinal motility. However these drugs have various drawbacks. Their effects on smooth muscle activity may be restricted to part of the digestive system, or may not be very efficient. On the other hand, their use is somewhat limited by side effects: drugs may not be specific for the motor functions of the gastrointestinal tract or not even for the gastrointestinal tract itself. The desirability of improving the promotility effects and eliminating the secondary effects of existing drugs constituted the rationale for developing cisapride. This aim was achieved by influencing--in a physiological way--the release of acetylcholine, the main neurotransmitter in the 'gut brain', the myenteric plexus.

Authors+Show Affiliations

Clinical Research Department, Janssen Research Foundation, Beerse, Belgium.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

2690319

Citation

Reyntjens, A. "Rationale for the Development of a Novel Gastrointestinal Prokinetic, Cisapride." Scandinavian Journal of Gastroenterology. Supplement, vol. 165, 1989, pp. 1-6; discussion 27-8.
Reyntjens A. Rationale for the development of a novel gastrointestinal prokinetic, cisapride. Scand J Gastroenterol Suppl. 1989;165:1-6; discussion 27-8.
Reyntjens, A. (1989). Rationale for the development of a novel gastrointestinal prokinetic, cisapride. Scandinavian Journal of Gastroenterology. Supplement, 165, pp. 1-6; discussion 27-8.
Reyntjens A. Rationale for the Development of a Novel Gastrointestinal Prokinetic, Cisapride. Scand J Gastroenterol Suppl. 1989;165:1-6; discussion 27-8. PubMed PMID: 2690319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rationale for the development of a novel gastrointestinal prokinetic, cisapride. A1 - Reyntjens,A, PY - 1989/1/1/pubmed PY - 1989/1/1/medline PY - 1989/1/1/entrez SP - 1-6; discussion 27-8 JF - Scandinavian journal of gastroenterology. Supplement JO - Scand. J. Gastroenterol. Suppl. VL - 165 N2 - Several promotility drugs have been used to correct disorders caused by disturbed gastrointestinal motility. However these drugs have various drawbacks. Their effects on smooth muscle activity may be restricted to part of the digestive system, or may not be very efficient. On the other hand, their use is somewhat limited by side effects: drugs may not be specific for the motor functions of the gastrointestinal tract or not even for the gastrointestinal tract itself. The desirability of improving the promotility effects and eliminating the secondary effects of existing drugs constituted the rationale for developing cisapride. This aim was achieved by influencing--in a physiological way--the release of acetylcholine, the main neurotransmitter in the 'gut brain', the myenteric plexus. SN - 0085-5928 UR - https://www.unboundmedicine.com/medline/citation/2690319/Rationale_for_the_development_of_a_novel_gastrointestinal_prokinetic_cisapride_ L2 - https://medlineplus.gov/gerd.html DB - PRIME DP - Unbound Medicine ER -